Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label basket study of ceritinib in ALK-positive advanced non-NSCLC malignancies
MOH_2017-03-21_000266Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceritinib in anaplastic large cell lymphoma (ALCL), inflammatory pseudotumor (IPT), glioblastoma (GBM) and 3 more (5 arms), sponsored by Novartis. Primary endpoint: Antitumor activity. Started Nov 2015; status: recruiting.
02
Drugs
ceritinib
03
Conditions
anaplastic large cell lymphoma (ALCL)inflammatory pseudotumor (IPT)glioblastoma (GBM)inflammatory breast cancer (IBC)solid neoplasms
Beyond the preview
Go deeper on MOH_2017-03-21_000266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-21_000266.